A White House Executive Order over the weekend has some healthcare company stocks soaring today. One big winner is Compass ...

Compass Pathways stock rallies as Trump’s new executive order aims at accelerating approval and research of psychedelic ...

Earlier this month, COMPASS Pathways welcomed a White House Executive Order aimed at accelerating treatments for serious mental illness, as it reported two positive phase 3 trials of its COMP360 ...

COMPASS Pathways (CMPS) stock jumped 25% after Trump's executive order on psychedelic research. Positive Phase 3 data boosts ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Shares of companies involved in psychedelic-tied therapies surged Monday after President Donald Trump signed an executive ...

Compass Pathways stock surged Monday after President Donald Trump signed an executive order tied to psychedelic drugs.

Over the weekend, President Donald Trump fast-tracked the approval process for psychedelic treatments for mental illnesses.

Some psychedelic stocks can rally after the executive order on the use of the this type of drug for mental health, ...

Trump executive order accelerates psychedelic drug approvals. AtaiBeckley surges 28%, Compass Pathways up 26% as FDA review ...

The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like ...